Inventiva SA (IVA)
Stock Price:
$13.76 USD
-0.74 (-5.10%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
528.09M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
n/a |
| Shares Out |
38.38M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 22, 2020 |
| Last Price |
$13.76 |
| Previous Close |
$14.50 |
| Change ($) |
-0.74 |
| Change (%) |
-5.10% |
| Day's Open |
13.92 |
| Day's Range |
13.57 - 14.50 |
| Day's Volume |
6,679 |
| 52-Week Range |
9.01 - 15.95 |
More Stats
| Market Cap |
528.09M |
| Enterprise Value |
485.84M |
| Earnings Date (est) |
Nov 12, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
38.38M |
| Float |
n/a |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
158,383 |
| Short Ratio |
6.40 |
| Short % of Float |
n/a |
| Beta |
1.14 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
11.25 |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
42.25M |
| Net Cash / Share |
1.10 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-24.39% |
| ROE |
-60.79% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
7 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$28.00*
(103.49% upside)
Low
18.0
Current: $13.76
High
38.0
Target: 28.00
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | 11.29 | 7.38 |
| Revenue Growth | 53.02% | - |
| Gross Profit | 11.29 | 7.38 |
| Operating Income | -30.31 | -32.90 |
| Net Income | -30.22 | -33.01 |
| Shares Outstanding | 23.52 | 20.54 |
| Earnings Per Share | -1.28 | -1.61 |
| Operating Cash Flow | -28.40 | -34.21 |
| Capital Expenditures | -0.13 | -0.55 |
| Free Cash Flow | -28.54 | -34.76 |
| Cash & Equivalents | 35.84 | 56.69 |
| Total Debt | 0.12 | 0.23 |
| Net Cash / Debt | 35.73 | 56.47 |
| Assets | 56.96 | 79.81 |
| Liabilities | 15.57 | 18.22 |
| Book Value | 41.39 | 61.60 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Inventiva SA |
| Country |
France |
| Employees |
86 |
| CEO |
Frédéric Cren |
Stock Information
| Ticker Symbol |
IVA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: IVA |
| IPO Date |
July 10, 2020 |
Description
Inventiva S.A., a biopharmaceutical company, develops drugs for the treatment of fibrotic, cancer, and orphan diseases. Its lead product candidate is Lanifibranor that is in Phase IIb clinical trial to treat nonalcoholic steatohepatitis and systemic sclerosis. The company also develops Odiparcil, which is in Phase IIa clinical trial primarily for the treatment of mucopolysaccharidosis type VI disease; YAP-TEAD that is in preclinical stage to treat malignant mesothelioma and lung cancer; NSD2 for the treatment of multiple myeloma; and EPICURE for immuno-oncology treatment. It has partnership collaborations with the Institut Curie in the field of oncology; AbbVie for developing ROR? project that is used for the treatment of autoimmune diseases, as well as other projects relating to fibrosis; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.